Skip To Main Content
Armaghan-e-Rehman Mansoor on Muck Rack

Armaghan-e-Rehman Mansoor

As seen in: Infectious Diseases News, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Armaghan-e-Rehman

Contact Armaghan-e-Rehman, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Experience with dalbavancin for long-term antimicrobial suppression of left ventricular assist device infections

|
By Mansoor AE, Cabrera NL, Armaghan-e-Rehman Mansoor, Tamara Krekel
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (627) Issue with article?

Staff at nonacute-care facilities report increased stress during pandemic

|
By Caitlyn Stulpin Verified, Carol L. DiBerardino Verified, Armaghan-e-Rehman Mansoor
| Infectious Diseases News Verified
Source/Disclosures Disclosures: The authors report no relevant financial disclosures. Source/Disclosures Disclosures: The authors report no relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: A survey revealed that 82% of HCP agreed that wearing a face mask could prevent COVID-19 acquisition.
Open in Who Shared Issue with article?

Future prospects of therapeutic clinical trials in acute myeloid leukemia

|
By Maliha Khan, Armaghan-e-Rehman Mansoor, Tapan M Kadia
| Future Medicine Verified
Acute myeloid leukemia (AML) is a markedly heterogeneous hematological malignancy that is most commonly seen in elderly adults. The response to current therapies to AML is quite variable, and very few new drugs have been recently approved for use in AML. This review aims to discuss the issues with current trial design for AML therapies, including trial end points, patient enrollment, cost of drug discovery and patient heterogeneity.
Open in Who Shared Issue with article?
See all 4 articles